Blog
RSS FeedPosted by Michael Wonder on 17 Jun 2021
Shared decision making underpins good health care
17 June 2021 - Shared decision making between service users and health care professionals is an integral part of health care, ...
Posted by Michael Wonder on 17 Jun 2021
Ontozry scores MHRA authorisation for focal-onset seizures
17 June 2021 - The MHRA has granted Arvelle Therapeutics’ Ontozry a marketing authorisation for the adjunctive treatment of focal-onset ...
Posted by Michael Wonder on 15 Jun 2021
How the patient voice is becoming vital for drug approval
14 June 2021 - Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a ...
Posted by Michael Wonder on 15 Jun 2021
GBT’s voxelotor is first sickle cell disease treatment to receive promising innovative medicine designation in the UK
14 June 2021 - Global Blood Therapeutics announced today that the MHRA in the United Kingdom has granted a Promising Innovative ...
Posted by Michael Wonder on 14 Jun 2021
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...
Posted by Michael Wonder on 14 Jun 2021
NICE to reassess Kyowa Kirin’s Poteligeo
14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...
Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...
Posted by Michael Wonder on 10 Jun 2021
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to ...
Posted by Michael Wonder on 10 Jun 2021
Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications
7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...
Posted by Michael Wonder on 09 Jun 2021
Amicus Therapeutics announces United Kingdom’s MHRA grants early access to AT-GAA
8 June 2021 - Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the ...
Posted by Michael Wonder on 08 Jun 2021
NICE recommends Tecentriq for first-line NSCLC
7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...
Posted by Michael Wonder on 08 Jun 2021
New Skyrizi (risankizumab) 150 mg presentation pre-filled pen and pre-filled syringe Approved by the MHRA
4 June 2021 - Approval based on results showing the new formulation of risankizumab 150 mg demonstrated bioequivalence to two injections ...
Posted by Michael Wonder on 07 Jun 2021
MHRA authorises Pfizer/BioNTech’s COVID-19 vaccine for 12 to 15 year-olds
7 June 2021 - The UK MHRA has extended the authorisation of Pfizer/BioNTech’s COVID-19 vaccine for use in children aged ...
Posted by Michael Wonder on 07 Jun 2021
GSK’s PD-1 inhibitor Jemperli approved in the UK
7 June 2021 - GSK's PD-1 inhibitor Jemperli has been authorised by the UK MHRA for the treatment of recurrent ...
Posted by Michael Wonder on 06 Jun 2021
NICE publishes appraisal consultation document for medicine for excessive daytime sleepiness
3 June 2021 - The Department of Health and Social Care has asked the NICE to produce guidance on using pitolisant ...